摘要
目的探讨miR-96与miR-103在肝癌组织中的表达及其与预后的关系。方法选取122例肝细胞癌患者作为本研究对象。聚合酶链式反应检测miR-96和miR-103表达水平,采用单因素和多因素Cox回归模型,探讨肝癌患者中位生存时间的危险因素并建立预测模型。结果肝癌组织中miR-96和miR-103相对表达水平均显著高于癌旁正常组织;肝癌组织中miR-96和miR-103的表达与肿瘤直径、淋巴结转移、临床分期及分化程度均有关(均P<0.05),而与性别、年龄及合并肝硬化等无关(P>0.05);所有患者随访60月,中位生存时间为37.8月。单因素分析结果显示:肝细胞癌患者中位生存时间与肿瘤直径、淋巴结转移、TNM分期、病理分化程度、miR-96和miR-103表达水平差异均有统计学意义(均P<0.05)。多因素分析结果显示:TNM分期为Ⅲ~Ⅳ、低分化、淋巴结转移、miR-96和miR-103高表达是肝癌患者中位生存时间独立危险因素。结论肝癌组织中miR-96和miR-103的高表达是患者预后差的独立影响因素,可作为原发性肝癌患者预后评估指标。
Objective To explore the expressions of miR-96 and miR-103 in hepatocellular carcinoma tissues and their relation with prognosis.Methods We selected 122 patients with hepatocellular carcinoma as the observation subjects.The expression levels of miR-96 and miR-103 were detected,and univariate and multivariate Cox regression models were used to analyze the risk factors of median survival time of hepatocellular carcinoma patients and to establish a predictive model.Results The relative expression levels of miR-96 and miR-103 in hepatocellular carcinoma tissues were significantly higher than those in paracancerous tissues;the expression of miR-96 and miR-103 in HCC were correlated with tumor diameter,lymph node metastasis,clinical stage and degree of differentiation(all P<0.05).All cases were followed up for 60 months,and the median survival time was 37.8 months.The expression of miR-96 and miR-103 in HCC were correlated with tumor diameter,lymph node metastasis,clinical stage and differentiation,but not with sex,age or liver cirrhosis.Multivariate analysis showed that TNM stageⅢ-Ⅳ,poor differentiation,lymph node metastasis,high expression of miR-96 and miR-103 were independent risk factors for median survival time of patients with primary hepatic carcinoma.Conclusion The high expression of miR-96 and miR-103 in liver cancer tissues are the independent influence factors of poor prognosis in primary hepatic carcinoma patients and could be used as the indexes of prognostic evaluation.
作者
肖维
李泉
张洪昌
韦杨年
XIAO Wei;LI Quan;ZHANG Hongchang;WEI Yangnian(Department of Hepatobiliary,Glandular and Peripheral Vascular Surgery,Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530011,China)
出处
《肿瘤防治研究》
CAS
CSCD
2020年第6期446-450,共5页
Cancer Research on Prevention and Treatment